Rice Hall James & Associates’s ADMA Biologics ADMA Stock Holding History

Rice Hall James & Associates’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,744	Closed	-$2.71M	–	241
2026 Q1	$2.71M	Buy	300,744 +8,809	+3%	+$139K	0.15%	141
2025 Q4	$5.32M	Sell	291,935 -31,718	-10%	-$535K	0.29%	82
2025 Q3	$4.74M	Sell	323,653 -66,962	-17%	-$1.15M	0.26%	93
2025 Q2	$7.11M	Sell	390,615 -18,247	-4%	-$372K	0.38%	67
2025 Q1	$8.11M	Sell	408,862 -2,163	-0.5%	-$37.4K	0.48%	53
2024 Q4	$7.05M	Sell	411,025 -7,011	-2%	-$132K	0.39%	62
2024 Q3	$8.36M	Sell	418,036 -739,219	-64%	-$11.5M	0.45%	59
2024 Q2	$12.9M	Sell	1,157,255 -49,244	-4%	-$413K	0.78%	37
2024 Q1	$7.96M	Buy	+1,206,499	New	+$6.59M	0.45%	57

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rice Hall James & Associates's ADMA Position: Q2 2026 in Review

Rice Hall James & Associates sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 300,744 shares — an estimated $2.71M sold.

Rice Hall James & Associates first reported a position in ADMA in Q1 2024 and held it in 9 quarters. The position peaked at $12.9M in Q2 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Rice Hall James & Associates reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
Rice Hall James & Associates sold 300,744 ADMA Biologics shares in Q2 2026, an estimated $2.71M.
Rice Hall James & Associates first reported a position in ADMA Biologics in Q1 2024 and held it in 9 quarters.
Rice Hall James & Associates's ADMA Biologics position peaked at $12.9M in Q2 2024.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.